Possibia

361

Last Update Posted: 2006-04-24

Recruiting has ended

All Genders

accepted

18 Years-70 Years

Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Autoimmunity in Inner Ear Disease

The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing loss in both ears. This condition is called autoimmune inner ear disease (AIED), because it is thought that the hearing loss is triggered by an autoimmune process. Treatment attempts to suppress or control this process with powerful anti-inflammatory drugs. This is a Phase III, outpatient study. All study participants will be assigned to one of four different groups testing the experimental use of drugs. The study is scheduled to run for 18 months, with a minimum of 11 visits per participant.

Eligibility

Relevant conditions:

Hearing Loss, Sensorineural

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.

locations

Data sourced from ClinicalTrials.gov